Genpact falls after results, guidance The shares are down over 15.8% at time of writing to $14.50. At that price, next support is at the fresh 52-week low set this morning at $13.68. Resistance is at the session high at $15.50. The $14 level on a multi-year chart basis is an important support. A break below it could lead to additional selling pressure.
NASCO and Genpact announces partnership to reimagine US healthcare NASCO and Genpact announced they will partner in an innovative effort to address the business operations needs of healthcare plans in the continually evolving U.S. healthcare market. NASCO and Genpact will transform health plan administration into a digitally-powered operating model that surrounds and extends NASCO's established, extremely efficient and scalable technology platform.